APA (7th ed.) Citation

Sircar, G., Goswami, R. P., Sircar, D., Ghosh, A., & Ghosh, P. (2018). Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial. Rheumatology (Oxford, England), 57(12), 2106-2113. https://doi.org/10.1093/rheumatology/key213

Chicago Style (17th ed.) Citation

Sircar, Geetabali, Rudra Prosad Goswami, Dipankar Sircar, Alakendu Ghosh, and Parasar Ghosh. "Intravenous Cyclophosphamide Vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial." Rheumatology (Oxford, England) 57, no. 12 (2018): 2106-2113. https://doi.org/10.1093/rheumatology/key213.

MLA (9th ed.) Citation

Sircar, Geetabali, et al. "Intravenous Cyclophosphamide Vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial." Rheumatology (Oxford, England), vol. 57, no. 12, 2018, pp. 2106-2113, https://doi.org/10.1093/rheumatology/key213.